Latest California Healthline Stories
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.
The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
Long before they receive a dementia diagnosis, many people begin to mismanage their finances as their memory, organizational skills and self-control falter.
Older patients with cancer, dementia or other serious illnesses should check with their doctors, but medical experts recommend the vaccine for most people.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Dr. Dale Bredesen is a well-known, well-respected neurologist. But his colleagues think the comprehensive Alzheimer’s program he’s marketing through a private company is a mixture of free-for-the-asking common sense and unproven interventions.
Because seniors are at higher risk of cognitive impairment, proponents say screening asymptomatic older adults is an important strategy to identify people who may be developing dementia and to improve their care. But the U.S. Preventive Services Task Force cited insufficient evidence the tests are helpful.
For those worried they have an elevated risk of Alzheimer’s and other forms of dementia, testing is an option. But words to the wise: It’s hardly foolproof and could even backfire by heightening your fear of memory loss.
For Alzheimer’s patients and their caregivers, social and emotional isolation is a threat. But hundreds of “Memory Cafes” around the country offer them a chance to be with others who understand, and to receive social and cognitive stimulation in the process.